Gastrointestinal stromal tumors (GISTs) are rare, but are the most common mesenchymal neoplasm of the gastrointestinal tract. The most common sites of metastasis are liver and peritoneum, while bone metastasis is rare. We report on a patient with skull metastasis after seven years of treat ment with imatinib for metastatic GIST. She underwent metastasectomy consisting of craniectomy with excision of the mass, and cranioplasty and continued treatment with imatinib and sunitinib, without evidence of cranial recurrence. She died of pneumonia sepsis one year after metastasecto my. Skull metastasis of GIST is a very rare presentation, and an aggressive multidisciplinary approach should be considered whenever possible.
INTRODUCTION
Gastrointestinal stromal tumors (GISTs) are rare, but are the most common mesenchymal neoplasm of the gastrointestinal tract, with an incidence of 10-20 cases per million 7) . These tumors can arise from anywhere in the gastrointestinal tract, and are thought to originate from interstitial cells of Cajal. The stomach is the most common site of origin (60-70%), and the small intestine (20-25%) and the large intestine (5-10%) are other usual sites 7) . It can present as localized disease, howev er, metastasis at presentation occurs in up to 50% of cases. In addition, localized disease can recur even after curative surgery. The most common sites to which gastrointestinal tumors me tastasize are liver and peritoneum, while lung, bone, or lymph node metastases are rare 13) . Surgical removal is the only curative option for localized GIST. In cases of metastasis, systemic treat ment is a main treatment modality. Before the imatinib era, there was no effective systemic treatment and survival of pa tients was usually poor.
Discovery of a gain-of-function muta tion in the c-kit protooncogene in GIST and development of imatinib, a tyrosine kinase inhibitor against the mutation, re sulted in a dramatic change of the prognosis of this disease 13) . As a consequence, median overall survival for metastatic GIST in the imatinib era is approximately five years 14) . Due to intro duction of very effective target agents, we now encounter me tastases of GIST, J Korean Neurosurg Soc 60 (1): 94-97 which used to be regarded as unusual sites of metastasis.
Here report on a patient with skull metastasis of GIST after seven years of imatinib treatment who underwent successful metastasectomy.
CASE REPORT
Ten years before the skull metastasis occurs, a 50-year old fe male patient complaining of dyspepsia was diagnosed with a GIST on the high body posterior wall of the stomach. She un derwent gastrectomy, and complete resection of the tumor without rupture was accomplished. The tumor measured 9× 7×6 cm in size with a mitotic rate of 52/50 high power field (HPF), less than 10% of necrosis, clear resection margin, and no lymph node metastasis. On immunohistochemical (IHC) staining, CD34 and c-kit were positive, while smooth muscle actin (SMA) and S-100 were focally positive. At that time, neither mutation analysis nor adjuvant imatinib treatment was a routine practice; therefore, she was followed-up with regular examination with out adjuvant treatment.
Nine years before the skull metastasis occurs, recurrence was observed in the abdominal wall and peritoneum. She started 400 mg/day of imatinib, and very good partial response (PR) was achieved and maintained. Although recurred GIST responded well to imatinib, she was suffering from grade 3 anorexia and lethargy, therefore, she took imatinib intermittently. The tumor grew during the imatinib-off period, but shrank again when she resumed imatinib treatment.
Her tumor was under control for seven years, until the peri toneal mass in the right lower quadrant showed progression and invasion of adjacent small bowel and ascending colon. She underwent debulking surgery (small bowel resection and re anastomosis, right hemicolectomy), and the mass measured 11×8 cm in size with 10-13/50 HPF and positive radial resec tion margin. After surgery, no gross mass was observed; how ever, the dose of imatinib was increased to 600 mg/day.
Ap proximately 16 months later, she found a lump on her head. The mass continued to grow, and CT scan of brain and abdomen which were taken three months later showed a large mass locat ed in the parietal cranial vault suppressing adjacent brain and a small single liver metastasis (Fig. 1) .
Subsequent MRI revealed a heterogeneously enhancing mass of approximately 7.7 cm ex tent involving the right parietal bone, parietal scalp, and parietal convexity with a heterogeneous signal intensity on a T1/T2 weighted image, multiple signal void on a T2 weighted image, and fatty marrow signal loss with enhancement ( Fig. 1) . She underwent craniectomy with excision of the mass, cranioplasty, and hepatic resection.
On surgical field, about 10×10 cm sized yellowish, relatively soft mass originating from skull was com pressing dura and brain parenchyma. Because mass adhered to the dura and invasion with seeding was grossly suspected, the bone, tumor, and dura were removed as a unit. Diagnosis of metastatic GIST was confirmed by pathologic examination ( trans formation was thought to result from drainage vein sacrifice during the operation. After conservative management and re habilitation, she recovered and was discharged from the hospi tal. Because the role of adjuvant radiotherapy for GIST is not established, we did not administer adjuvant radiotherapy. In stead, her imatinib dose was elevated to 800 mg/day thereafter, which she was not able to tolerate. After three months of rest, huge masses were found in the liver and peritoneal cavity. There was no recurrence in the cranium.
She started sunitinib treat ment 6 months after metastasectomy. Unfortunately, she was not able to tolerate sunitinib due to nausea and fatigue; there fore, after 1.5 month of sunitinib treatment, she rested for three months. As the masses progressed, she resumed sunitinib, when 1 year has passed since metastasectomy. A month after sunitinib resumption, she was admitted to the hospital via the emergency department for fever and dyspnea, and diagnosed with pneumonia. She died of acute respiratory distress syn drome one month later, when 14 months has passed since skull metastasectomy.
DISCUSSION
This case illustrates a woman who had skull metastasis of ima tinib-resistant GIST, which was treated by surgical removal. She lived for one year after craniectomy without evidence of cranial recurrence, and her cause of death was not disease progression itself but infection and respiratory failure.
Although malignant GISTs can theoretically metastasize any organ, they obviously have some tropism for specific organs. They tend to stay in the abdominal cavity even in very advanced stage 13) . Only a few papers have reported bone metastases of GIST 1, 5, 6, 8, 10) , and the most frequent site of bone metastases re ported were spine and pelvis 5, 6) . Skull metastasis is even rarer. To the best of our knowledge, only five cases of skull metastasis have been reported 2, 3, 9, 11, 15) . Presenting symptoms depended on the location of metastasis, with skull base or periorbital metas tases being more symptomatic [2] [3] [4] 11, 15) .
Management of metastatic GIST should be customized according to symptom, location of disease, available treatment modalities, and condition of the patient. Our patient underwent debulking craniectomy, because we believed that previous long-term imatinib treatment produced a resistant clone, a huge met astatic mass would soon provoke neurologic symptoms, and en-bloc resection would be possible. Debulking surgery is a viable option even in patients with metastatic GIST, especially when disease status is stable or shows limited progression 12) . If a resis tant clone is removed completely, long term survival could be achieved. Our patient survived 10 years after recurrence. Con sidering that median overall survival of metastatic or recurrent GIST receiving imatinib treatment is five years and nine-year overall survival rate is 34% 14) , she lived for a comparatively long period after recurrence. We believe that appropriate metastasec tomy (peritoneal, hepatic, and skull metastasis) during the treat ment course had an important role in her long-term survival.
Traditionally, bone metastasis of GIST was thought to be very rare; however, long-term survival of our patient enabled 
CONCLUSION
We present the case of a female with skull metastasis of GIST after a long term treatment with imatinib successfully managed by metastasectomy. Symptomatic skull metastasis from GIST is very rare, and an aggressive multidisciplinary approach includ ing surgery and chemotherapy plays an important role in its management.
